AILSEVAX

Ailsevaxis based on the 3 core elements: neo-antigens discovery, cancer vaccine development, effective adjuvants and delivery platforms. AilseVax are developing innovations across all three domains to develop the next generation of cancer vaccine therapies.Founded by oncologists, immunologists, data scientists and an experienced management team with excellent track-record in building multiple successful life sciences ventures... AilseVax has developed the AltRNA8V™ antigen discovery engine to exploit the untapped wealth of antigenic potential encoded in abnormal RNAs and their translation products... AilseVax's goal is to use our proprietary technology platforms to develop cancer vaccines that work in multiple patient populations

Also known as: AilseVax Ltd.

Primary location: San Diego United States